Patents by Inventor Julia Zh. Gao

Julia Zh. Gao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS OF A SRC/ABL INHIBITOR
    Publication number: 20130122093
    Abstract: The invention relates to pharmaceutical compositions of ?N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and to methods of using the pharmaceutical compositions in the treatment of oncological and immunological disorders
    Type: Application
    Filed: January 7, 2013
    Publication date: May 16, 2013
    Inventors: Julia ZH Gao, Rajeshwar Motheram
  • ORAL ADMINISTRATION OF N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-1,3-THIAZOLE-5-CARBOXAMIDE AND SALTS THEREOF
    Publication number: 20080275009
    Abstract: Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof.
    Type: Application
    Filed: July 7, 2008
    Publication date: November 6, 2008
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ramakrishnan Chidambaram, George M. Derbin, Masaki Endo, Julia ZH Gao, Tu Lee, Rajeshwar Motheram, William Lawrence Parker, Victor W. Rosso, Sailesh A. Varia
  • Efavirenz tablet formulation having unique biopharmaceutical characteristics
    Publication number: 20030124186
    Abstract: The present invention provides an efavirenz tablet formulation which, when administered as a single dose to a subject, provides a mean maximum plasma concentration (Cmax) of about 4 &mgr;M to about 14 &mgr;M, a mean time of maximum plasma concentration (Tmax) of about 2 hours to about 5 hours, and a mean area under the plasma concentration versus time curve from time zero to time infinity (AUC) of about 190 &mgr;M·hour to about 470 &mgr;M·hour.
    Type: Application
    Filed: November 26, 2002
    Publication date: July 3, 2003
    Inventors: Munir A. Hussain, Julia Zh. Gao, Rajeshwar Motheram, David B. Gray